Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status approved; investigational
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 55111-893; 82920-001; 72205-007; 72485-205; 62331-043; 16714-467; 51407-640; 55111-496; 55111-497; 61269-475; 65162-844; 15308-0714; 54893-0002; 59651-205; 64980-277; 70756-815; 68001-487; 69097-949; 72205-006; 63482-099; 72969-094; 16729-072; 59923-721; 61269-470; 0054-0271; 69539-019; 0093-7473; 64980-276; 0054-0272; 69097-948; 72606-554; 53104-7618; 55512-0015; 0004-1100; 51407-639; 67877-459; 68001-488; 69539-020; 35369-0010; 16729-073; 51407-096; 62756-238; 62756-239; 65162-843; 67877-458; 59651-204; 72485-204; 72606-555; 49452-1713; 68554-0033; 0004-1101; 0093-7474; 51407-095; 60687-149; 0378-2511; 70756-816; 53183-4009; 54245-7014; 65129-1241; 81955-0001; 16714-468; 59923-722
UNII 6804DJ8Z9U
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Megacolon07.02.05.0020.000392%-
Melaena07.12.02.004; 24.07.02.013---
Melanocytic naevus16.26.01.007; 23.10.01.0070.000448%-
Memory impairment17.03.02.003; 19.20.01.003--
Menopausal symptoms21.02.02.002---
Mental disability26.01.01.001---
Mesenteric artery thrombosis07.15.02.008; 24.01.08.0030.000168%-
Metabolic acidosis14.01.01.0030.001511%-
Metastases to liver09.04.02.004; 16.22.02.0010.002574%-
Metastases to lung16.22.02.002; 22.08.01.0050.001612%-
Migraine17.14.02.001; 24.03.05.003---
Mitral valve incompetence02.07.01.0020.000280%-
Monoplegia17.01.04.0030.000112%-
Mood altered19.04.02.007---
Mood swings19.04.03.001---
Morphoea10.04.07.002; 15.06.01.008; 23.03.02.0110.000168%-
Mouth haemorrhage07.05.02.001; 24.07.02.0140.000280%
Mouth ulceration07.05.06.0040.001880%-
Mucosal inflammation08.01.06.0020.017853%-
Mucosal ulceration08.01.06.003---
Mucous stools07.01.03.0060.000112%-
Muscle spasms15.05.03.004--
Muscular weakness15.05.06.001; 17.05.03.005--
Mutism17.02.08.007; 19.19.01.0010.000112%-
Myalgia15.05.02.001--
Myelopathy17.10.01.0070.000112%-
Myocardial infarction02.02.02.007; 24.04.04.009--
Myocardial ischaemia02.02.02.008; 24.04.04.0100.001287%-
Myocarditis02.04.03.001--
Myoclonus17.02.05.008---
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 31 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene